Eye On Five

41 Things On Tap at OIS@ASCRS

41 Things On Tap at OIS@ASCRS

By Rich Kirkner | April 4, 2018

There are 41 different sessions, panels, and presentations happening at OIS@ASCRS 2018 – including five different breakout sessions on everything from dry eye to emerging…

Read More
Who Will be Making News Next Month?

What’s Happening in the Month Ahead: January 2018

By Rich Kirkner | January 4, 2018

pSivida Set to File 3-year Durasert NDA pSivida Corp. this month expects to file a New Drug Application with the Food and Drug Administration for…

Read More
OIS-Eye-On-Five

Eye on Five – July Edition

By Rich Kirkner | August 1, 2017

FDA Shoots Down Ocular Therapeutix’s Dextenza NDA The Food and Drug Administration (FDA) denied approval of Ocular Therapeutix’s resubmitted New Drug Application (NDA) for its Dextenza…

Read More
OIS-Eye-On-Five

Eye on Five – June Edition

By Rich Kirkner | July 5, 2017

Novartis Reports Positive Phase III Results for RTH258 Novartis reported that RTH258 (brolucizumab) 6 mg met the primary and key secondary endpoints of non-inferiority compared…

Read More
OIS-Eye-On-Five

Eye on Five – May Edition

By Rich Kirkner | June 1, 2017

Alcon Launches Multifocal Toric IOL at ASCRS Alcon seized the platform of ASCRS 2017 to launch its AcrySof IQ ReSTOR +2.5 multifocal toric intraocular lens…

Read More
OIS-Eye-On-Five

Eye on Five – April Edition

By Rich Kirkner | May 1, 2017

FDA Green Lights Allergan’s Tear Neurostimulator Allergan has been granted marketing authorization from the FDA for its TrueTear Intranasal Tear Neurostimulator. This is the only FDA-approved…

Read More
OIS-Eye-On-Five

Eye on Five – March Edition

By Rich Kirkner | March 31, 2017

Ora Retained to Develop Cannabinoids for Eye Disease Ora Inc., a global contract research organization that specializes in ophthalmology, took the plunge into medical marijuana…

Read More
OIS-Eye-On-Five

Eye on Five – February Edition

By Rich Kirkner | March 2, 2017

Envisia Candidate Achieves Endpoint for IOP Lowering Envisia Therapeutics released Phase II results showing that its ENV515 candidate (travoprost XR) achieved clinically meaningful intraocular pressure…

Read More
OIS-Eye-On-Five

Eye on Five – January Edition

By Rich Kirkner | February 1, 2017

Alcon Turnaround Has Novartis Exploring Spin-off With its Alcon turnaround plans on track, Novartis AG revealed it is exploring options that include spinning off Alcon…

Read More
OIS - Eye on Five

Eye on Five – November Edition

By Rich Kirkner | November 30, 2016

Trump Bump Fuels Biotech, Pharma Stocks Pharma and biotech stocks surged in the week after Donald Trump’s election, with the OIS Index jumping 13% and…

Read More
OIS - Eye on Five

Eye on Five – October Edition

By Rich Kirkner | November 1, 2016

Sustained-Release Eylea Focus of Collaboration Ocular Therapeutix Inc. and Regeneron entered into a collaboration agreement to develop a sustained-release formulation of Regeneron’s Eylea (aflibercept), currently…

Read More
OIS - Eye on Five

Eye on Five – September Edition

By Rich Kirkner | October 3, 2016

Johnson & Johnson Moves to Buy AMO The evolution of the ophthalmology sector continued with this month’s news that Johnson & Johnson Vision Care would…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.